Current Projects

Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment (PREDICT). Vanderbilt University has launched PREDICT, a program of preemptive pharmacogenetics testing coupled to real-time decision support: when a drug is prescribed to a patient with pharmacogenetic variants important for that drug, the electronic healthcare system responds with real-time advice on dose adjustment or alternate drugs.  [Dan RodenJosh DennyJosh Peterson

Pharmacogenomics Research Network (PGRN). The mission of the PGRN is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects. The Vanderbilt site of PGRN focuses on understanding the molecular and cellular basis of drug-induced long QT syndrome and the Stevens-Johnson/Toxic Epidermal Necrolysis Syndrome and using phenomic scanning in the EMR to identify potential new adverse drug reactions and drug repurposing opportunities.  [Dan RodenElizabeth PhillipsJosh Denny]

Electronic Medical Records and Genomics (eMERGE) Network. Vanderbilt has been a site in the eMERGE Network since 2007. eMERGE is a consortium of U.S. medical research institutions that brings together researchers with a wide range of expertise in genomics, statistics, ethics, informatics, and clinical medicine from leading medical research institutions across the country to conduct research in genomics, including discovery, clinical implementation, and public resources. Vanderbilt is home to an eMERGE Network Coordinating Center that provides a suite of support to the Network. [Dan RodenJosh Denny, Josh Peterson

Integrated, Individualized, and Intelligent Prescribing (I3P) – the Vanderbilt site of the NHGRI’s Implementing GeNomics In PracTicE (IGNITE) Network. The Vanderbilt I3P site of IGNITE is performing a multi-site test of the implementation of genomic medicine by embedding genetic information within electronic medical records in diverse healthcare environments to show that this is not only achievable but also can alter physician behavior toward a vision of personalized medicine. I3P is part of the larger IGNITE program, which is driven by the need to accelerate the pace of incorporating patients’ genomic information into clinical care and to carefully evaluate implementation efforts. [Josh DennyMia LevyJosh Peterson

Mid-South Clinical Data Research Network (CDRN through PCORI). The Mid-South CDRN focuses on health systems that reach rural and urban populations and is developing the tools and capacities to conduct pragmatic research that fits seamlessly into healthcare operations. [Russell Rothman

Data and Research Center, Precision Medicine Initiative All of Us Research ProgramThis program, now rebranded as the All of Us program, is a national study of genetic, environmental, and lifestyle factors affecting the health of a million or more people.  In July 2016, Vanderbilt was chosen to lead the creation and operation of the PMI Data and Research Support Center. The role of the center is to acquire and organize what will become an enormous and extraordinarily diverse dataset of precision medicine indicators and to provide research support and analysis tools to the scientists who will mine it. Major partners include the Broad Institute and Verily/Google.  [Josh Denny

Center of Excellence in Precision Medicine and Population HealthThe Vanderbilt-Miami-Meharry Center of Excellence in Precision Medicine and Population Health brings together institutions and faculty with substantial expertise in precision medicine and health disparities research among African Americans and Latinos/Hispanics and leverages unique assets and resources to develop novel methods and approaches to advance population health. [Consuelo Wilkins

Undiagnosed Diseases Network (UDN). The Vanderbilt Center for Undiagnosed Diseases is a site in NHGRI’s UDN that brings together clinical and research experts to solve challenging medical mysteries. The Vanderbilt UDN clinical site has an emphasis on heritable heart and lung diseases, as well as pharmacogenetic, arrhythmia and autonomic disorders in adults, and metabolic and other genetic problems in children. [John PhillipsJohn Newman

Programs in Drug Hypersensitivity. Research programs in drug hypersensitivity exist under the umbrella of the PGRN, and  related clinical activities take place through the Drug Allergy Clinic, which provides expert care for individuals with all types of allergic reactions to medicines. The clinic's mission is to eliminate uncertainty for individuals with potential drug allergies and to improve the safety and effectiveness of drug therapy. [Elizabeth Phillips]

Phenome-Wide Association Studies (PheWAS) analyze many phenotypes compared to a single genetic variant (or other attribute). This method was originally described using electronic medical record (EMR) data from the Vanderbilt DNA biobank, BioVU, but can also be applied to other richly phenotyped sets. The site provides a catalog of PheWAS results. [Josh Denny]